Genetic Signatures Ltd (AU:GSS) — Market Cap & Net Worth
Market Cap & Net Worth: Genetic Signatures Ltd (GSS)
Genetic Signatures Ltd (AU:GSS) has a market capitalization of $10.61 Million (AU$14.99 Million) as of June 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26910 globally and #1303 in its home market, demonstrating a -5.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genetic Signatures Ltd's stock price AU$0.07 by its total outstanding shares 227138828 (227.14 Million). Review debt load of Genetic Signatures Ltd to assess the company's total debt and financial obligations.
Genetic Signatures Ltd Market Cap History: 2015 to 2026
Genetic Signatures Ltd's market capitalization history from 2015 to 2026. Data shows change from $133.43 Million to $10.61 Million (-16.38% CAGR).
Genetic Signatures Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genetic Signatures Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.53x
Genetic Signatures Ltd's market cap is 2.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $70.63 Million | $3.27 Million | -$3.03 Million | 21.63x | N/A |
| 2017 | $51.01 Million | $4.06 Million | -$2.67 Million | 12.56x | N/A |
| 2018 | $125.58 Million | $4.99 Million | -$3.25 Million | 25.15x | N/A |
| 2019 | $161.70 Million | $7.02 Million | -$3.49 Million | 23.02x | N/A |
| 2020 | $315.53 Million | $11.26 Million | -$2.09 Million | 28.01x | N/A |
| 2021 | $280.99 Million | $28.28 Million | $1.76 Million | 9.93x | 160.02x |
| 2022 | $138.13 Million | $35.42 Million | $3.06 Million | 3.90x | 45.10x |
| 2023 | $69.91 Million | $16.94 Million | -$14.05 Million | 4.13x | N/A |
| 2024 | $101.25 Million | $9.77 Million | -$17.86 Million | 10.37x | N/A |
| 2025 | $40.18 Million | $15.90 Million | -$20.10 Million | 2.53x | N/A |
Competitor Companies of GSS by Market Capitalization
Companies near Genetic Signatures Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Genetic Signatures Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.98 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #181 globally with a market cap of $127.92 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #622 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #662 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.98 Billion | $473.72 |
| #181 | Danaher Corporation | NYSE:DHR | $127.92 Billion | $181.10 |
| #622 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $570.00 |
| #662 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Genetic Signatures Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Genetic Signatures Ltd's market cap moved from $133.43 Million to $ 10.61 Million, with a yearly change of -16.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$10.61 Million | -73.60% |
| 2025 | AU$40.18 Million | -60.32% |
| 2024 | AU$101.25 Million | +44.83% |
| 2023 | AU$69.91 Million | -49.39% |
| 2022 | AU$138.13 Million | -50.84% |
| 2021 | AU$280.99 Million | -10.95% |
| 2020 | AU$315.53 Million | +95.14% |
| 2019 | AU$161.70 Million | +28.76% |
| 2018 | AU$125.58 Million | +146.19% |
| 2017 | AU$51.01 Million | -27.78% |
| 2016 | AU$70.63 Million | -47.06% |
| 2015 | AU$133.43 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Genetic Signatures Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.61 Million USD |
| MoneyControl | $10.61 Million USD |
| MarketWatch | $10.61 Million USD |
| marketcap.company | $10.61 Million USD |
| Reuters | $10.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more